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Background: Cardiac hypertrophy is a compensatory stage of the heart in response to stress such as pressure
overload (PO), which can develop into heart failure (HF) if left untreated. Resveratrol has been reported to prevent the
development of hypertrophy and contractile dysfunction induced by PO. However, other studies found that resveratrol
treatment for a longer period of time failed to regress cardiac hypertrophy. The aim of this study is to determine the
timing of resveratrol treatment to achieve antihypertrophic effect and investigate whether resveratrol prevents the
development of HF through preservation of myocardium structure and modulation of Ca2+ handling proteins.
Methods: To generate rats with cardiac hypertrophy, male Sprague–Dawley rats were subjected to PO (aortic banding
procedure) for 4 weeks. Sham-operated animals served as controls. Rats with cardiac hypertrophy were given resveratrol
(4 mg/kg/day) for 4, 6, and 8 weeks, respectively. Histological and echocardiographic analysis and transmission electron
microscopy were performed to assess cardiac structure and function. The levels of Ca2+ handling proteins were
measured by western blot analysis.
Results: Histological analysis showed that resveratrol treatment regressed developed cardiac hypertrophy at 8 and 10
weeks postsurgery, but not at 12 weeks. However, resveratrol strongly and continuously prevented the development of
cardiac dysfunction and dilation of cardiac chamber as evaluated by echocardiography and H&E staining of heart
cross-sections. In addition, PO-induced cardiac fibrosis was completely inhibited by resveratrol treatment. Resveratrol
markedly prevented the disrupted myocardium but partially rescued mitochondrial abnormality in banded rats.
Moreover, resveratrol prevented the alteration of Ca2+ handling proteins induced by aortic banding, including
downregulation of sarcoplasmic reticulum Ca2+ ATPase 2 (SERCA2) and ryanodine receptor 2 (RyR2), hypophosphorylated
phospholamban (PLB), upregulation of Na+/Ca2+-exchangers (NCX1) and increased expression and phosphorylation of
Ca2+/calmodulin -dependent protein kinase II (CaMKII). Moreover, resveratrol alleviated the decreased SERCA activity
induced by aortic banding.
Conclusions: Resveratrol effectively prevented the transition from compensatory to decompensatory stage of cardiac
hypertrophy induced by PO, but this effect is dependent on the timing of treatment. We suggest that resveratrol may
exert beneficial effects on cardiac hypertrophy through protection of cardiac structure and modulation of Ca2+
handling proteins.
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Heart failure (HF) is a major cause of hospitalization
and mortality worldwide [1]. Increased hemodynamic
load is one of the major contributors to the development
of HF. Cardiac hypertrophy is considered to be an adap-
tive response to pressure or volume overload, which is
characterized by the enlargement of heart muscle. Al-
though the initial phase is beneficial in maintaining
cardiac function, prolonged hypertrophy will lead to
deleterious consequences and eventually HF. Nowadays,
many medicines, such as β-adrenergic receptor blockers,
angiotensin-converting enzyme inhibitors, angiotensin-
receptor blockers and diuretics, have been universally
used to treat cardiac hypertrophy and HF. These medi-
cines can be effective to partially relieve the symptoms
of HF, but cannot reverse the progression of HF. In fact,
mortality rates of HF still approach about 20% per year
[1]. Therefore, it is critically important to explore alter-
native approaches to prevent or reverse the progression
of cardiac hypertrophy and HF.
Previous studies including The Dietary Approaches to
Stop Hypertension (DASH) trial and Lyon Diet Heart
Study have demonstrated that increased intake of fruits
and vegetables lowered blood pressure in patients with
hypertension, reduced the incidence of cardiovascular
diseases, and improved survival after myocardial infarction
[2]. Furthermore, several studies reported that resveratrol
(trans-3, 5, 49- trihydroxystilbene), which is a phenolic
phytoalexin and presents in grapes, berries and red wine,
alleviated contractile dysfunction, reversed pressure over-
load (PO)-induced cardiac hypertrophy [1,3,4] and re-
duced cardiovascular mortality [5]. Wojciechowski P [1]
and Juric D [2] found that resveratrol treatment for
2 weeks regressed cardiac hypertrophy in aortic banded
rats. However, Ste’phanie Rimbaud demonstrated that res-
veratrol treatment for 8 weeks did not counteract cardiac
hypertrophy in the Dahl salt-sensitive (DSS) rats fed with
a high-salt diet (HS-NT) [5]. These inconsistent results in-
dicated that resveratrol may reverse cardiac hypertrophy
in a timing-dependant manner. In this study, we investi-
gated the optimal timing of resveratrol treatment to
achieve antihypertrophic effect in rats subjected to PO.
Additionally, it is well demonstrated that resveratrol
protects against the development of HF by improving
contractile functions [1-5]. However, precise mecha-
nisms of its action remain unclear. The normal myocar-
dial structure is essential for cardiac contraction. The
most prominent ultrastructural alteration in HF is the
loss of contractile elements, which significantly results in
reduced cardiac function. Therefore, it is worthwhile to
investigate whether resveratrol ameliorates ultrastruc-
tural abnormalities in failing hearts induced by PO.
Ca2+ cycling, a critical process referring to the mobi-
lization of intracellular Ca2+ in excitation-contraction (EC)coupling, determines cardiac contractility and relaxation.
It is now generally accepted that defective Ca2+ handling
proteins in the cycling play an important role in HF patho-
physiology. The key defects in Ca2+ cycling occur at the
level of the sarcoplasmic reticulum (SR), a Ca2+ storage
bulk in muscle. The SR Ca2+ release channel (ryanodine
receptor 2, RyR2) is oxidized, nitrosylated, and hyperpho-
sphorylated, resulting in “leaky” channels and depletion of
Ca2+ from the SR in failing hearts. Downregulated SR Ca2+
ATPase 2a (SERCA2a) and hypophosphorylated phospho-
lamban (PLB) contribute to impaired SR Ca2+ uptake that
conspires with leaky RyR2 to deplete SR Ca
2+ in failing
hearts [6]. Accordingly, the other goal of this study is to
verify the hypothesis that resveratrol fixes Ca2+ handling




The investigation conforms to the Guide for the Care
and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication No. 85–
23, revised 1985). Male Sprague–Dawley rats weighing
80-100 g were obtained from Central Animal Care Ser-
vices at Southern Medical University and subjected to
the abdominal aortic banding procedure for induction of
PO. Briefly, rats were kept in a room with constant
temperature of 26°C, humidity of 55%, and a 12 h light:
12 h dark cycle throughout the study. Animals were
given standard rat chow and tap water ad libitum. All
rats were anesthetized for surgery with 10% chloral hy-
drate (3 ml/kg). A midline laparotomy was performed,
and the suprarenal abdominal aorta was exposed. The
aorta between the branches of celiac artery and anterior
mesenteric artery was tied off by a 4–0 silk suture with a
blunt 24-gauge needle as a guide. Sham-operated rats
were served as controls and subjected to the same sur-
geries except for the creation of the aortic band. Resver-
atrol treatment started from 4 weeks postsurgery when
LV hypertrophy ocurred, as indicated by the results of
echocardiography, and aortic banded rats were divided
into treated and untreated subgroups. Resveratrol (Sigma,
4 mg/kg/d) was suspended in 0.5% carboxymethylcellulose
(CMC, Sigma) dissolved in 0.9% saline. This solution was
administered to treated rats by oral gavages for 4, 6 and
8 weeks, respectively. 0.9% saline was used as a vehicle to
treat sham and banded animals.
Echocardiography
At 4, 8, 10 and 12 weeks postsurgery, rats from all
groups were weighed and anesthetized with chloral hy-
drate. Transthoracic two-dimensionally guided M-mode
echocardiography was performed using an IE33 echocar-
diographic system (Philips Medical Systems, Nederland
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lowing parameters were measured: percentage of left
ventricular (LV) fractional shortening (FS), LV ejection
fraction (EF), maximal velocity through left ventricular
outflow tract (Vmax), Cardiac output, LV pressure half-
time, LV internal dimensions at both diastole and systole
(LVIDd and LVIDs, respectively), LV posterior wall dimen-
sions at both diastole and systole (LVPWd and LVPWs, re-
spectively), and interventricular septal dimensions at both
diastole and systole (IVSd and IVSs, respectively).
Organ weight and histological analysis
Body weight, heart and LV with septum were weighed,
and the LV mass-to-body weight ratio (LVm/BW) was
calculated. LV samples were fixed in 10% neutral buff-
ered formalin, embedded with liquid paraffin, and sec-
tioned into 6 μm in thickness. Myocyte cross-sectional
area was used for the evaluation of the degree of LV
hypertrophy. Briefly, sections were stained with hema-
toxylin and eosin (HE) and examined under a light micro-
scope (Nikon ECLIPSE Ti-U). Five random fields from
each of 4 sections per animal were analyzed, and 10 ~ 15
myocytes per section were measured. The quantification
of diameter and area of myocytes were determined with
Image Pro Plus 6.0 (Media Cybernetics, Carlsbad, CA). To
assess fibrosis, sections were stained with a Masson tri-
chrome kit (Baso, BA4079) according to manufacturer’s
instructions and stained sections were examined under a
light microscope. Interstitial and perivascular fibrosis con-
tent were quantified in tissue sections using Image Pro
Plus 6.0 as the percentage of connective tissue per cross-
sectional surface area. The cross sectional area of LV
chamber was also measured.
Transmission Electron Microscopy (TEM)
Hearts were perfused and fixed in 2.5% glutaraldehyde
in 0.1 M sodium cacodylate buffer followed by post-
fixation with 2% osmium tetroxide in 0.1 M phosphate
buffer (pH 7.4) for 2 h at room temperature. The tissue
cubes were then dehydrated in an ascending series of
ethanol solutions, followed by acetone dehydration. The
tissue cubes were embedded with Embed 812 resin over-
night at 37°C. 40 ~ 60 nm ultrathin sections were cut on
an ultramicrotome, picked up on grids, and stained with
a solution of lead citrate and uranyl acetate. The sections
were then observed, and photographs were taken under
a Hitachi 7650 electron microscope.
Western blot analysis
LV tissues frozen in liquid nitrogen were pulverized and
homogenized in a lysis buffer containing 20 mM Tris–
HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM
EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM
beta-glycerophosphate, 1 mM Na3VO4, 1 μg/ml leupeptin(20 ml/g tissue) and 1 mM phenylmethylsulfonyl fluoride.
Protein samples (20 ~ 25 μg) were separated by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to polyvinylidene difluoride (PVDF)
membranes. PVDF membranes were probed with the
following primary antibodies: anti-Ca2+/calmodulin-
dependent protein kinase II (CaMKII) antibody (Abcam,
1:1000 dilution), anti-phospho-CaMKII (Thr286) antibody
(p-CaMKII, CST, 1:1000 dilution), anti-PLB antibody
(Abcam, 1:1000 dilution), anti-phospho-PLB (S16) anti-
body (p-PLB, Abcam, 1:1500 dilution), anti-SERCA2 anti-
body (Abcam, 1:1000 dilution), anti-RyR2 antibody (Abcam,
1:1000 dilution) or anti-Na+/Ca2+-exchangers (NCX1) anti-
body (Abcam, 1:1000 dilution). Appropriate secondary
antibodies were used to detect the corresponding primary
antibodies, and the antibody-antigen complexes in all
membranes were detected by the ECL PLUS kit (Bio-Rad).
The protein bands were quantified by Image Pro Plus 6.0.
SERCA activity measurements
Samples of the left ventricle were prepared as the method
previously described by Lizotte E [7]. The ATPase activity
in samples was assessed with an ATPase activity assay kit
(Nanjing Jiancheng Bioengineering Institute, Nanjing,
China) based on a colorimetric estimation of ATP
hydrolysis-produced inorganic phosphate. According to
manufacturer’s instructions, the reactions were initiated by
adding samples into the ATPase activity assay buffer. Fol-
lowing 10 min-reaction at 37°C, the contents of inorganic
phosphate in samples were determined by optical densities
(OD) measured with the Infinite M1000 PRO plate reader
(Tecan, Switzerland) at 636 nm. The protein concentration
in samples was determined by BCA kit (Pierce Company).
The enzyme activity was defined as the contents of inor-
ganic phosphorus (μmol) per mg total protein and hour.
Statistical analysis
All statistical analyses were performed using the SPSS
Statistical software (version 17.0). Values are expressed
as mean ± standard error (SEM). One-way analysis of
variance was used to analyze the differences between the
means of groups, followed by Tukey post hoc test. A
value of P <0.05 was considered significant.
Results
Establishment of hypertrophic model
Cardiac structure and function in rats were assessed by
echocardiography at 4 weeks postsurgery (Additional
file 1A). The parameters of LV wall thickness including
IVSs, IVSd, LVPWs and LVPWd were significantly in-
creased in aortic banded rats compared with sham rats
(Additional file 1B). On the contrary, LVIDs was signifi-
cantly decreased in aortic banded rats compared with
sham rats, whereas no significant difference in LVIDd was
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Moreover, the parameters of systolic function (EF and FS)
were significantly increased in banded rats compared to
sham rats (Additional file 1D). These data indicated that
the rat model of compensatory cardiac hypertrophy in-
duced by aortic banding was successfully established.Antihypertrophic effect of resveratrol
Histological analysis showed that surface areas and di-
ameters of cardiomyocytes were remarkably increased at
8, 10 and 12 weeks postsurgery in aortic banded rats
compared with sham rats, but decreased by 27%, 14% at
8 weeks and 46%, 26% at 10 weeks postsurgery respect-
ively in resveratrol-treated rats compared to banded rats.
However, we found that resveratrol treatment failed to
reverse enlargement in cardiomyocytes at 12 weeks post-
surgery (Figure 1A-C).
The LVm/BW was increased by 29%, 54% and 59% in
banded rats at 8, 10 and 12 weeks postsurgery respectively
compared to sham rats. The LVm/BW in resveratrol-
treated rats was not significantly different at 8 weeks post-
surgery and significantly increased by 35% and 26% at 10
and 12 weeks postsurgery compared with sham rats,
whereas was lower than banded rats at 10 and 12 weeks
(Figure 1D).Figure 1 Effects of resveratrol on the size of cardiomyocytes (n = 3) a
(A) Photomicrographs of left ventricular tissue sections stained by hematox
Data are mean ± SEM. *P < 0.05 **P < 0.01 vs. sham rats; †P < 0.05 ††P < 0.01Effect of resveratrol on LV chamber
H&E staining analysis of cardiac cross-sections revealed
dilation of LV in banded rats at 8, 10 and 12 weeks post-
surgery. Resveratrol treatment showed a significant al-
leviation of LV dilation induced by aortic band at
indicated time point (Figure 2A, B). Consistent with the
histological data, LVIDd and LVIDs detected by echocar-
diographic analysis were also increased in banded rats
compared with sham rats at 10 and 12 weeks postsur-
gery, and this effect was eliminated by resveratrol treat-
ment (Figure 2C, D).Effect of resveratrol on cardiac systolic function
Echocardiographic analysis of cardiac function was car-
ried out at 8, 10, and 12 weeks postsurgery in sham,
banded and resveratrol-treated rats. We found that sys-
tolic functional parameters (EF, FS and Vmax) in banded
rats were decreased continuously compared to sham rats
at 8, 10, and 12 weeks postsurgery. Of note, resveratrol
treatment significantly increased EF by 14%, 15%, 26%,
FS by 30%, 32%, 26%, and Vmax by 30%, 26%, 25% at 8,
10, 12 weeks postsurgery respectively, compared with
banded rats. FS and Vmax in resveratrol-treated rats
were even remarkably higher than sham rats at 12 weeks
postsurgery (Figure 3).nd the LV mass-to-body weight ratio (LVm/BW) (n = 6).
ylin and eosin. (B) Myocyte diameter. (C) Myocyte area. (D) LVm/BW.
vs. banded rats.
Figure 2 Effect of resveratrol on left ventricular (LV) chamber (n = 4 ~ 7). (A) Photomicrographs of the cross sectional area of LV chamber
stained by hematoxylin and eosin. (B) Chamber diameter of LV. (C) LV internal dimensions at systole (LVIDs). (D) LV internal dimensions at
diastole (LVIDd). Both LVIDs and LVIDd were detected by echocardiographic analysis. Data are mean ± SEM. *P < 0.05 **P < 0.01 vs. sham rats;
†P < 0.05 ††P < 0.01 vs. banded rats.
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Fibrosis in the cross-sections of heart was stained blue
with the Masson’s trichrome kit. We detected that both
interstitial and perivascular fibrosis were increased in
aortic banded rats at 8, 10 and 12 weeks postsurgery re-
spectively, compared to sham rats. Interestingly, resvera-
trol treatment significantly reduced interstitial fibrosis
by 38%, 45%, 56% and perivascular fibrosis by 56%, 53%,
60% at 8, 10 and 12 weeks postsurgery respectively,
compared with banded rats, suggesting that resveratrol
treatment can inhibit myocardial fibrosis caused by aor-
tic banding (Figure 4).
Effect of resveratrol on myocardium ultrastructure
TEM revealed the disrupted myocardium and disorga-
nized mitochondria with abnormal cristae structure in
banded rats at 12 weeks postsurgery (Figure 5). Cardiac
muscle fibers from sham rats exhibited normal ultrastruc-
tural morphology, characterized by laterally aligned myofi-
brils with highly organized sarcomeres and elongated
mitochondria packed tightly in strands running between
myofibrils. However, in myocardium from banded rats,
myofibrils were fragmented, disrupted and degraded, with
disorganized arrays of sarcomeres. Mitochondria appearedrounded or irregular, extensive swelling, abnormally
clumped or dispersed, and occasionally broken cristae.
Some mitochondria were markedly degraded in cristae
with lucent matrix and vacuolation. In myocardium from
resveratrol-treated rats, the ultrastructure of cardiomyo-
cytes was effectively maintained and nearly similar to
those in sham rats, exhibiting slightly disrupted myofibrils.
The mitochondria from resveratrol-treated rats appeared
to be irregular shapes, obvious swollen and mildly
clumped, but degraded cristae and vacuolations as shown
in banded rats were not found in resveratrol-treated rats.
Additionally, the apparent loss of myofibrils was only de-
tected in hearts from banded, but not from resveratrol-
treated rats (Figure 5).
Effect of resveratrol on Ca2+ handling proteins
The levels of total PLB in hearts from banded rats were
markedly increased compared with sham rats, and en-
hanced by 2.2-fold especially at 12 weeks postsurgery.
Resveratrol treatment continuously alleviated the in-
creased total PLB expression. On the contrary, the levels
of p-PLB which were normalized by the levels of
GADPH or total PLB were remarkably decreased at 8,
10 and 12 weeks postsurgery in banded rats relative to
Figure 3 Effect of resveratrol on left ventricular (LV) systolic function (n = 4 ~ 7). (A) Representative pictures of echocardiography.
(B) Fractional shortening (FS). (C) Ejection fraction (EF). (D) Maximal velocity through left ventricular outflow tract (Vmax). Data are mean ± SEM.
*P < 0.05 **P < 0.01 vs. sham rats; †P < 0.05 ††P < 0.01 vs. banded rats.
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ment (Figure 6A-D).
The levels of NCX1 were increased continuously in
banded rats compared with sham rats. Resveratrol com-
pletely prevented the upregulation of NCX1 induced by
aortic band and even significantly lowered it relative to
sham group (Figure 6A, E). On the contrary, SERCA2
levels were markedly decreased in banded rats compared
with sham rats at 8, 10 and 12 weeks postsurgery, ac-
companied with decreased ratio of SERCA2 to PLB and
SERCA activity. Notably, resveratrol treatment enhanced
the levels of SERCA2 and the ratio of SERCA2 to PLB,
and prevented the decreased SERCA activity caused by
aortic banding (Figure 6A, F-H).
The levels of total CaMKII in hearts from banded rats
were unchanged at 8 weeks postsurgery, but increased
significantly at 10 and 12 weeks postsurgery compared
with sham rats. Resveratrol remarkably alleviated the
elevation of total CaMKII induced by aortic banding.
Accordingly, the levels of p-CaMKII were progressively
increased at 8, 10 and 12 weeks postsurgery in banded
rats, which were completely prevented by resveratrol
(Figure 7A-C). However, due to sharply rising of total
CaMKII, the ratio of p-CaMKII to total CaMKII in
banded rats was no different with sham rats at 12 weeks
postsurgery, and even lower at 10 weeks postsurgery(Figure 7A, D). Meanwhile, the significant decreases in
RyR2 levels were observed in banded rats compared with
sham rats at 8, 10 and 12 weeks postsurgery, and the re-
duction of RyR2 levels induced by aortic banding was
prevented by resveratrol treatment (Figure 7A, E).
Discussion
This study provides several new findings showing that
resveratrol prevents the transition from cardiac hyper-
trophy to HF induced by PO. First, we demonstrated
resveratrol reversed LV hypertrophy induced by PO with
time limitation. Second, we showed that resveratrol
strongly and continuously prevented the cardiac struc-
tural and functional exacerbation due to PO. Third, we
showed that resveratrol exerted multiple actions that
may contribute to the beneficial effects including (1) in-
hibition of cardiac fibrosis, (2) prevention of myocardium
ultrastructural alterations, (3) modulation of activation
and expression of Ca2+ handling proteins.
Antihypertrophic effect of resveratrol has a time limit
Antihypertrophic effect of resveratrol and its analogue
has been documented in different experimental settings
of PO [1,3,4,8-12]. In this study, 4 weeks after aortic
banding surgery, rats developed PO-induced centric
hypertrophy, as indicated by significant increase in wall
Figure 4 Effect of resveratrol on cardiac fibrosis in left ventricular (LV) myocardium (n = 4). (A) Representative photomicrographs of
Masson trichrome staining for interstitial fibrosis showing myocardium in red and fibrosis in blue. (B) Quantification of interstitial fibrosis.
(C) Representative photomicrographs of Masson trichrome staining for perivascular fibrosis. (D) Quantification of perivascular fibrosis. Data are
mean ± SEM. *P < 0.05, **P < 0.01 vs. sham rats; †P < 0.05, ††P < 0.01 vs. banded rats.
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vious studies, resveratrol treatment regressed developed
cardiac hypertrophy at 8 and 10 weeks postsurgery.
However, resveratrol did not prevent cardiac hyper-
trophy at the late stage of the experiment, as shown by
histological analysis. The data of LVm/BW also suggested
that the effect of resveratrol was receded gradually as PO
was sustained. Developed cardiac hypertrophy in treated
rats was further confirmed by echocardiography analysis,
which showed a marked increase in wall thickness com-
pared with sham rats at 12 weeks postsurgery (see
Additional file 2). This novel finding indicated that the
timing of treatment is a critical factor for antihypertrophic
effect of resveratrol.
Resveratrol prevented the development of
decompensatory phase
4-week aortic banding caused compensatory centric
hypertrophy characterized by high contractile function
of LV, increased thickness of LV wall and decreased
LVIDs. However, with long-standing untreated PO, LV
systolic performance decreased and LV dilatation oc-
curred, which are the key features of decompensatory
phase, namely HF. Resveratrol treatment effectively
preserved cardiac systolic function and LV chamberdimension. Previous studies demonstrated that resvera-
trol improved contractile function with abolishing car-
diac hypertrophy caused by PO [1,3]. Interestingly, we
found that resveratrol continuously exerted cardiopro-
tective effects in banded rats and these effects sustained
to decompensatory stage of HF even though its antihy-
pertrophic effect was absent. Similarly, Ste’phanie Rimbaud
found that resveratrol treatment exerted beneficial pro-
tective effects on survival and cardiac contraction in DSS
rats fed with HS-NT which is a hypertensive model of HF
[5]. However, the mechanism underlying the development
of HF in DSS rats is apparently different from aortic
banded rats.
Cardioprotective mechanisms of resveratrol
The development of HF is associated with marked myo-
cardial fibrosis which is characterized by excessive extra-
cellular matrix (ECM) deposition and myocardial stiffness
[13]. Limiting pathological myocardial fibrosis represents a
potential therapeutic target to prevent HF. Previous stud-
ies have demonstrated that resveratrol has beneficial ef-
fects to reduce cardiac fibrosis in a variety of pathological
models [14,15]. For instance, resveratrol alleviated cardiac
fibrosis in spontaneously hypertensive rats [16] and de-
creased left ventricular interstitial and perivascular fibrosis
Figure 5 Effects of resveratrol on myocardium ultrastructure detected by transmission electron microscopy (TEM). Representative TEM
image illustrating (A) ultrastructure of myocardium with 15000 × Magnification, (B) mitochondria (white arrow) and (C) myofilaments (black
arrow) with 30000 × Magnification in sham, banded and resveratrol-treated rats.
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inhibited interstitial and perivascular fibrosis due to PO,
indicative of the improvement of myocardial compliance
and diastolic function. Indeed, increased LV pressure half-
time, an index of diastolic heart function, was detected in
banded rats, but prevented by resveratrol (see Additional
file 3). Meanwhile, inhibition of cardiac fibrosis by resvera-
trol could explain the findings that LVm/BW in treated
rats was remarkably lower than in banded rats at 12 weekspostsurgery while no difference in the size of cardiomyo-
cytes was detected by histological analysis between two
groups.
Second, we found that resveratrol protected against
myocardial ultrastructural abnormalities induced by PO.
The most obvious detriment to myocardial ultrastructure
induced by PO was decrease of myofibrils as a result of
rupture and degradation of myofilaments. Notably, resver-
atrol treatment normalized myocardial ultrastructure as
Figure 6 Effects of resveratrol on the expressions of proteins responsible for SR Ca2+ load and sarcoplasmic reticulum Ca2+-ATPase
activity (n = 3). (A) Representative western blot from each group. (B) The levels of Phospholamban (PLB). (C) The levels of Phospho-PLB (S16)
(p-PLB). (D) The ratio of p-PLB to PLB. (E) The levels of Na+/Ca2+-exchangers (NCX 1). (F) The levels of Sarcoplasmic reticulum Ca
2+-ATPase (SERCA 2).
(G) The ratio of SERCA 2 to PLB. (H) SERCA activity. Levels of proteins were quantified by densitometry and normalized against GADPH. Data are
mean ± SEM. *P < 0.05 **P < 0.01 vs. sham rats; †P < 0.05 ††P < 0.01 vs. banded rats.
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which may be attributed to multiple mechanisms benefi-
cial to cell survival including prevention of cardiomyocyte
apoptosis, regulation of autophagy, and reduction of oxi-
dative stress [14,18-20]. The other striking abnormality
caused by PO was swollen and disordered mitochondria
revealed by TEM. Resveratrol only partially prevented
mitochondrial lesions. However, other studies demon-
strated that resveratrol significantly attenuated the abnor-
mality of mitochondrial ultrastructure in sepsis-induced
myocardial depression with a large dose (30 mg/kg or
60 mg/kg) [21], and preserved mitochondrial function and
biogenesis contributing to improve cardiac energy me-
tabolism and reduce oxidative stress in other models
[5,20,22,23]. This difference could be explained by thediversity of resveratrol dosage, the period of treatment, the
stage of HF and animal models.
Ca2+ cycling which refers to the release and reuptake of
intracellular Ca2+ is highly regulated in cardiomyocytes
and determines the process of cardiac muscle contraction
and relaxation. Defects in the regulation of Ca2+ handling
proteins contribute to HF. To our knowledge, the effects
of resveratrol on Ca2+ handling proteins in HF remain un-
clear. Impaired SERCA2 function and enhanced NCX ac-
tivity have been proposed as causes of reduced SR Ca2+
load in HF. Moreover, PLB, a regulator of the affinity of
SERCA2 for Ca
2+, balances SR Ca2+ uptake through inhi-
biting the affinity of SERCA2 for Ca
2+ by unphosphory-
lated PLB and relieving this inhibition by phosphorylation.
As a negative regulator of SERCA2, hypophosphorylated
Figure 7 Effects of resveratrol on protein expressions of Ca2+/calmodulin-dependent protein kinase II (CaMK II), phospho-CaMKII
(Thr286) (p-CaMK II) and ryanodine receptor (RyR2) (n = 3). (A) Representative western blot from each group. (B) The levels of CaMK II.
(C) The levels of p-CaMK II. (D) The ratio of p-CaMK II to CaMK II. (E) The levels of RyR2. Levels of proteins were quantified by densitometry and
normalized against GADPH. Data are mean ± SEM. *P < 0.05 **P < 0.01 vs. sham rats; †P < 0.05 ††P < 0.01 vs. banded rats.
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failing hearts. Accordingly, both SERCA2 overexpression
and PLB inhibition have been designed as therapeutic
strategies for HF [6]. In this study, PO caused substantially
decreased SERCA2 expression and ATPase activity, elevated
NCX1, increased PLB and decreased p-PLB, indicating
that SR Ca2+ load in this animal model is deficient, conse-
quently leading to impaired contractile function. Resvera-
trol effectively upregulated SERCA2 levels, ATPase activity
and the ratio of phosphorylated to unphosphorylated PLB,
accompanied by a significant downregulation of NCX1, in-
dicative of improved SR Ca2+ load in hearts. Consistent
with our results, a previous study showed that increased
SERCA2a expression by resveratrol improved contractile
function in chronic type 1 diabetes [12].Additionally, we detected a significant increase in ex-
pression and phosphorylation of CaMKII due to PO. It
has been reported that CaMKII hyperphosphorylation of
RyR2 accounts for excessive diastolic SR Ca
2+ leak in
non-ischemic (aortic banding) cardiomyopathy, but not
in ischemia (post-MI) in which PKA phosphorylation of
RyR2 is involved [24]. This leads to increased RyR2 open
probability and a diastolic SR Ca2+ leak because of a
higher sensitivity to Ca2+-induced Ca2+ release at low
cytoplasmic Ca2+ concentrations. In our experiment, res-
veratrol attenuated the increase in CaMKII level and
completely inhibited hyperphosphorylation of CaMKII.
It has been demonstrated that RyR2 leak was inhibited
through inhibition of CaMKII phosphorylation. Knock-
in mice with an inactivated CaMKII phosphorylation site
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http://www.translational-medicine.com/content/12/1/323on RyR2 had lower SR Ca
2+ leak and improved SR Ca2+
load, and were relatively protected from HF develop-
ment after transverse aortic constriction [25]. In patients
with HF, CaMKII- but not PKA-dependent RyR2 phos-
phorylation was significantly increased, accompanied by
increased SR Ca2+ leak, reduced systolic Ca2+ transients,
depletion of SR Ca2+ storage and elevated diastolic Ca2+
levels. Moreover, CaMKII inhibition, but not inhibition
of PKA yielded a reduction of the SR Ca2+ leak [25].
Therefore, we speculate that CaMKII downregulation by
resveratrol plays a major role in preventing the develop-
ment of cardiac dysfunction in aortic banded animals via
inhibition of RyR2 leak.
Although the activity of RyR2 channel in HF was in-
vestigated in many studies, very little is known about ex-
pression of RyR2 and its significance in failing heart. We
found that RyR2 protein expression was significantly de-
creased in myocardium of HF and resveratrol effectively
enhanced the expression of RyR2. We speculate that
downregulation of RyR2 may decrease systolic Ca
2+
release and impair cardiac contractility. Similarly, Kubalova
et al. found that RyR2 content in failing hearts was de-
creased to approximately half of control values, but the
levels of other proteins of the Ca2+ release channel com-
plex such as triadin and junctin were not changed. The
altered stoichiometry of triadin and junctin to RyR2 may
increase activity of RyR2, thus leading to the abnormal
Ca2+ handling in HF [26].
A prevailing theory is that one of the major mecha-
nisms proposed to underlie resveratrol mediated cardio-
protection is reduction of oxidative stress [4,27,28].
Polydatin, a resveratrol glucoside, has been shown to
prevent enhanced Ca2+ spark-mediated SR leak by redu-
cing oxidative stress in RyR2 in burn-traumatized heart,
leading to protection of cardiac function against burn in-
jury [29]. Further studies are needed to understand
whether reduction of oxidative stress by resveratrol
could regulate RyR2 and other Ca
2+ handling proteins in
aortic banded rats.
Conclusions
These data demonstrated that resveratrol treatment pre-
vented cardiac hypertrophy induced by PO with time-
limitation and inhibited the development of HF via
improving cardiac structure and function. The novel
findings on mechanisms underlying cardioprotection of
resveratrol include protection of myocardium ultrastruc-
ture and regulation of global Ca2+ handling proteins.
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Additional file 1: Two-dimensionally guided M-mode
echocardiographic measurement of wall thickness (IVSs, IVSd,
LVPWs and LVPWd) (A and B), chamber dimensions (LVIDs andLVIDd) (A and C), systolic parameters (FS and EF) (A and D) of left
ventricular (LV) in sham and banded rats at 4 weeks postsurgery
(n = 6~13). Data are mean±SEM. *P<0.05 **P<0.01 vs. sham rats.
Additional file 2: Two-dimensionally guided M-mode
echocardiographic measurement of IVSd (A), IVSs (B), LVPWd
(C) and LVPWs (D) in sham, banded and resveratrol-treated rats at
8, 10 and 12 weeks postsurgery (n = 4~7). Data are mean±SEM.
*P<0.05 vs. sham rats; †P<0.05 vs. banded rats.
Additional file 3: Effect of resveratrol on left ventricular (LV)
cardiac output and pressure half-time (n = 4~7). (A) Representative
pictures of echocardiography. (B) Cardiac output. (C) Pressure half-time.
Data are mean±SEM. *P<0.05 **P<0.01 vs. sham rats; †P<0.05 ††P<0.01 vs.
banded rats.
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